SG11201811745UA - T cell compositions for immunotherapy - Google Patents
T cell compositions for immunotherapyInfo
- Publication number
- SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- june
- pct
- immunotherapy
- cell compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 5
- 108700012920 TNF Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012099 Alexa Fluor family Substances 0.000 abstract 1
- 101710145634 Antigen 1 Proteins 0.000 abstract 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 abstract 1
- 101150106931 IFNG gene Proteins 0.000 abstract 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 abstract 1
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 241000656145 Thyrsites atun Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000004172 quinoline yellow Substances 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355533P | 2016-06-28 | 2016-06-28 | |
| US201662355506P | 2016-06-28 | 2016-06-28 | |
| US201662355458P | 2016-06-28 | 2016-06-28 | |
| PCT/US2017/039846 WO2018005712A1 (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811745UA true SG11201811745UA (en) | 2019-01-30 |
Family
ID=60787739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811745UA SG11201811745UA (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237819A1 (https=) |
| EP (1) | EP3487990A4 (https=) |
| JP (3) | JP7034955B2 (https=) |
| KR (1) | KR20190037243A (https=) |
| CN (1) | CN109715788A (https=) |
| AU (3) | AU2017290119A1 (https=) |
| CA (1) | CA3068387A1 (https=) |
| IL (1) | IL263896A (https=) |
| MX (1) | MX2019000180A (https=) |
| SG (1) | SG11201811745UA (https=) |
| WO (1) | WO2018005712A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| IL294055A (en) * | 2015-03-20 | 2022-08-01 | Childrens Nat Medical Ct | Generating virus or other antigen-specific t cells from a naive t cell population |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US11401507B2 (en) | 2016-11-17 | 2022-08-02 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| EP3572502B1 (en) * | 2017-01-20 | 2023-01-11 | Kyoto University | Method for producing cd8alpha +beta + cytotoxic t cells |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US11793867B2 (en) * | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JP7198602B2 (ja) * | 2018-07-11 | 2023-01-04 | カワサキモータース株式会社 | 自動二輪車 |
| EP3831936A4 (en) * | 2018-07-31 | 2022-04-13 | Thyas Co. Ltd. | METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS |
| AU2019314888A1 (en) * | 2018-07-31 | 2021-02-18 | Polybiocept Gmbh | Production and selection of tumor uber reactive immune cells (TURICs) |
| JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
| JP7495137B2 (ja) * | 2018-08-10 | 2024-06-04 | ユーティレックス カンパニー リミテッド | 癌抗原特異的細胞傷害性ｔ細胞 |
| US20210388317A1 (en) * | 2018-10-26 | 2021-12-16 | Shinshu University | High-efficiency method for producing genetically modified cells |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
| US20220064597A1 (en) * | 2018-12-18 | 2022-03-03 | Beth Israel Deaconess Medical Center, Inc. | Generation of organoid-primed T (opT) cells with memory phenotype |
| EP3908293A4 (en) * | 2019-01-07 | 2023-01-11 | Children's National Medical Center | EX VIVO ACTIVATED T LYMPHOCYTE COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2020221310B2 (en) * | 2019-02-14 | 2025-10-16 | Research Institute At Nationwide Children's Hospital | Use of a stimulating agent to assay immune cell potency |
| CA3132028A1 (en) * | 2019-03-30 | 2020-10-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| CN120172958A (zh) | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| WO2020243729A1 (en) * | 2019-05-31 | 2020-12-03 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
| CA3145196A1 (en) * | 2019-06-24 | 2020-12-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| CA3162703A1 (en) * | 2019-11-27 | 2021-06-03 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| US20230028788A1 (en) * | 2019-12-23 | 2023-01-26 | Baylor College Of Medicine | T cell performance assay as a prognostic factor for clinical outcome |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| AU2021388167A1 (en) * | 2020-11-25 | 2023-07-06 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| CN113564116B (zh) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ce的制备方法 |
| CN113481157B (zh) * | 2021-07-21 | 2023-03-17 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞的优化制备方法 |
| CN113512529B (zh) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ab的制备方法 |
| WO2023039410A1 (en) * | 2021-09-08 | 2023-03-16 | KSQ Therapeutics, Inc. | Lymphocyte potency assay |
| US20250325668A1 (en) * | 2021-10-08 | 2025-10-23 | Baylor College Of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| JP2023064787A (ja) * | 2021-10-27 | 2023-05-12 | 国立大学法人京都大学 | Ｔ細胞の品質評価方法、および当該方法に用いる試薬 |
| WO2023178140A2 (en) * | 2022-03-18 | 2023-09-21 | St. Jude Children's Research Hospital, Inc. | Method for preparing t cells for adoptive t cell therapy |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| KR102566680B1 (ko) * | 2022-09-28 | 2023-08-14 | (주)포에버엔케이 | 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2330678C (en) * | 1998-05-11 | 2009-04-07 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
| RU2327487C2 (ru) | 2002-08-08 | 2008-06-27 | Бейлор Колледж Оф Медисин | Выделение и идентификация т-клеток |
| SI2119726T2 (en) | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| EP3101122B1 (en) * | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| US9114100B2 (en) * | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| CN103906531A (zh) * | 2011-05-26 | 2014-07-02 | 金纽斯生物科技投资有限责任公司 | 调节的免疫优势疗法 |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| BR112017004270B1 (pt) * | 2014-09-04 | 2023-03-07 | Stemcell Technologies Inc | Método de ativação de células t ou células nk |
| US10993997B2 (en) * | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| EP3322801A1 (en) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
-
2017
- 2017-06-28 KR KR1020197002828A patent/KR20190037243A/ko not_active Ceased
- 2017-06-28 WO PCT/US2017/039846 patent/WO2018005712A1/en not_active Ceased
- 2017-06-28 AU AU2017290119A patent/AU2017290119A1/en not_active Abandoned
- 2017-06-28 US US16/312,023 patent/US20200237819A1/en not_active Abandoned
- 2017-06-28 CN CN201780053540.8A patent/CN109715788A/zh active Pending
- 2017-06-28 JP JP2018569009A patent/JP7034955B2/ja active Active
- 2017-06-28 EP EP17821200.7A patent/EP3487990A4/en active Pending
- 2017-06-28 CA CA3068387A patent/CA3068387A1/en active Pending
- 2017-06-28 MX MX2019000180A patent/MX2019000180A/es unknown
- 2017-06-28 SG SG11201811745UA patent/SG11201811745UA/en unknown
-
2018
- 2018-12-23 IL IL263896A patent/IL263896A/en unknown
-
2022
- 2022-03-02 JP JP2022031731A patent/JP2022066355A/ja active Pending
- 2022-06-16 US US17/807,213 patent/US20230145991A1/en active Pending
-
2023
- 2023-10-26 AU AU2023254998A patent/AU2023254998A1/en not_active Abandoned
-
2024
- 2024-05-22 JP JP2024083379A patent/JP2024103547A/ja active Pending
-
2026
- 2026-03-24 AU AU2026202260A patent/AU2026202260A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019519246A (ja) | 2019-07-11 |
| AU2017290119A1 (en) | 2019-01-24 |
| US20230145991A1 (en) | 2023-05-11 |
| EP3487990A1 (en) | 2019-05-29 |
| JP2022066355A (ja) | 2022-04-28 |
| AU2026202260A1 (en) | 2026-04-09 |
| EP3487990A4 (en) | 2020-07-29 |
| MX2019000180A (es) | 2019-11-05 |
| CN109715788A (zh) | 2019-05-03 |
| WO2018005712A1 (en) | 2018-01-04 |
| AU2023254998A1 (en) | 2023-11-16 |
| KR20190037243A (ko) | 2019-04-05 |
| JP2024103547A (ja) | 2024-08-01 |
| CA3068387A1 (en) | 2018-01-04 |
| JP7034955B2 (ja) | 2022-03-14 |
| US20200237819A1 (en) | 2020-07-30 |
| IL263896A (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811745UA (en) | T cell compositions for immunotherapy | |
| SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
| SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201807300PA (en) | Uterine cancer treatments | |
| SG11201908337VA (en) | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201909652WA (en) | Neoantigen identification, manufacture, and use | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201806400XA (en) | Replicative transposon system | |
| SG11201801384YA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810591VA (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| SG11201407818PA (en) | High-capacity storage of digital information in dna | |
| SG11201809751XA (en) | Egfr inhibitor compounds |